Table 1 Characters of the eligible trials
Author | Year | Pts | Treatment arm | Control arm |
|---|---|---|---|---|
Unselected | ||||
  Lilenbaum, R.[10] | 2008 | 103 | Erlotinib | Paclitaxel + Carboplatin |
  Crino, L. (INVITE)[6] | 2008 | 196 | Gefitinib | Vinorelbine |
  Agarwal, S.[4] | 2010 | 35 | Gefitinib | Gemcitabine + Carboplatin |
  Gridelli, C. (TORCH)[15] | 2010 | 760 | Erlotinib | Vinorelbine + Carboplatin |
Clinical-Selected | ||||
  Lee, J. S. (First-SIGNAL)[16] | 2009 | 313 | Gefitinib | Gemcitabine + Cisplatin |
2009 | 780 | Gefitinib | Paclitaxel + Carboplatin | |
EGFR mutation Selected | ||||
  Mitsudomi, T. (WJTOG3405)[19] | 2010 | 177 | Gefitinib | Docetaxel + Cisplatin |
  Maemondo, M. (NEJSG)[20] | 2010 | 230 | Gefitinib | Paclitaxel + Carboplatin |
2009 | 261 | Gefitinib | Paclitaxel + Carboplatin | |
  Zhou, C. (OPTIMAL)[21] | 2011 | 165 | Erlotinib | Gemcitabine + Carboplatin |
  Rosell, R. (EURTAC)[22] | 2011 | 174 | Erlotinib | Platium based |